Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 35

1.

Effect of multiple-dose osimertinib on the pharmacokinetics of simvastatin and rosuvastatin.

Harvey RD, Aransay NR, Isambert N, Lee JS, Arkenau T, Vansteenkiste J, Dickinson PA, Bui K, Weilert D, So K, Thomas K, Vishwanathan K.

Br J Clin Pharmacol. 2018 Dec;84(12):2877-2888. doi: 10.1111/bcp.13753. Epub 2018 Oct 10.

PMID:
30171779
2.

The effect of itraconazole and rifampicin on the pharmacokinetics of osimertinib.

Vishwanathan K, Dickinson PA, So K, Thomas K, Chen YM, De Castro Carpeño J, Dingemans AC, Kim HR, Kim JH, Krebs MG, Chih-Hsin Yang J, Bui K, Weilert D, Harvey RD.

Br J Clin Pharmacol. 2018 Jun;84(6):1156-1169. doi: 10.1111/bcp.13534. Epub 2018 Mar 23.

PMID:
29381826
3.

The Effect of Food or Omeprazole on the Pharmacokinetics of Osimertinib in Patients With Non-Small-Cell Lung Cancer and in Healthy Volunteers.

Vishwanathan K, Dickinson PA, Bui K, Cassier PA, Greystoke A, Lisbon E, Moreno V, So K, Thomas K, Weilert D, Yap TA, Plummer R.

J Clin Pharmacol. 2018 Apr;58(4):474-484. doi: 10.1002/jcph.1035. Epub 2017 Nov 26.

PMID:
29178442
4.

Optimizing Clinical Drug Product Performance: Applying Biopharmaceutics Risk Assessment Roadmap (BioRAM) and the BioRAM Scoring Grid.

Dickinson PA, Kesisoglou F, Flanagan T, Martinez MN, Mistry HB, Crison JR, Polli JE, Cruañes MT, Serajuddin ATM, Müllertz A, Cook JA, Selen A.

J Pharm Sci. 2016 Nov;105(11):3243-3255. doi: 10.1016/j.xphs.2016.07.024. Epub 2016 Sep 19. Review.

PMID:
27659159
5.

Systems Pharmacology Modeling of Prostate-Specific Antigen in Patients With Prostate Cancer Treated With an Androgen Receptor Antagonist and Down-Regulator.

Mistry HB, Fabre MA, Young J, Clack G, Dickinson PA.

CPT Pharmacometrics Syst Pharmacol. 2016 May;5(5):258-63. doi: 10.1002/psp4.12066. Epub 2016 May 15.

6.

Metabolic Disposition of Osimertinib in Rats, Dogs, and Humans: Insights into a Drug Designed to Bind Covalently to a Cysteine Residue of Epidermal Growth Factor Receptor.

Dickinson PA, Cantarini MV, Collier J, Frewer P, Martin S, Pickup K, Ballard P.

Drug Metab Dispos. 2016 Aug;44(8):1201-12. doi: 10.1124/dmd.115.069203. Epub 2016 May 25.

PMID:
27226351
7.

Osimertinib Western and Asian clinical pharmacokinetics in patients and healthy volunteers: implications for formulation, dose, and dosing frequency in pivotal clinical studies.

Planchard D, Brown KH, Kim DW, Kim SW, Ohe Y, Felip E, Leese P, Cantarini M, Vishwanathan K, Jänne PA, Ranson M, Dickinson PA.

Cancer Chemother Pharmacol. 2016 Apr;77(4):767-76. doi: 10.1007/s00280-016-2992-z. Epub 2016 Feb 22.

PMID:
26902828
8.

AZD9291 in EGFR inhibitor-resistant non-small-cell lung cancer.

Jänne PA, Yang JC, Kim DW, Planchard D, Ohe Y, Ramalingam SS, Ahn MJ, Kim SW, Su WC, Horn L, Haggstrom D, Felip E, Kim JH, Frewer P, Cantarini M, Brown KH, Dickinson PA, Ghiorghiu S, Ranson M.

N Engl J Med. 2015 Apr 30;372(18):1689-99. doi: 10.1056/NEJMoa1411817.

9.

AZD3514, an oral selective androgen receptor down-regulator in patients with castration-resistant prostate cancer - results of two parallel first-in-human phase I studies.

Omlin A, Jones RJ, van der Noll R, Satoh T, Niwakawa M, Smith SA, Graham J, Ong M, Finkelman RD, Schellens JH, Zivi A, Crespo M, Riisnaes R, Nava-Rodrigues D, Malone MD, Dive C, Sloane R, Moore D, Alumkal JJ, Dymond A, Dickinson PA, Ranson M, Clack G, de Bono J, Elliott T.

Invest New Drugs. 2015 Jun;33(3):679-90. doi: 10.1007/s10637-015-0235-5. Epub 2015 Apr 30.

PMID:
25920479
10.

The biopharmaceutics risk assessment roadmap for optimizing clinical drug product performance.

Selen A, Dickinson PA, Müllertz A, Crison JR, Mistry HB, Cruañes MT, Martinez MN, Lennernäs H, Wigal TL, Swinney DC, Polli JE, Serajuddin ATM, Cook JA, Dressman JB.

J Pharm Sci. 2014 Nov;103(11):3377-3397. doi: 10.1002/jps.24162. Epub 2014 Sep 24. Review.

PMID:
25256402
11.

Transition state theory and the dynamics of hard disks.

Barnett-Jones M, Dickinson PA, Godfrey MJ, Grundy T, Moore MA.

Phys Rev E Stat Nonlin Soft Matter Phys. 2013 Nov;88(5):052132. Epub 2013 Nov 25.

PMID:
24329239
12.

In vitro models for the prediction of in vivo performance of oral dosage forms.

Kostewicz ES, Abrahamsson B, Brewster M, Brouwers J, Butler J, Carlert S, Dickinson PA, Dressman J, Holm R, Klein S, Mann J, McAllister M, Minekus M, Muenster U, Müllertz A, Verwei M, Vertzoni M, Weitschies W, Augustijns P.

Eur J Pharm Sci. 2014 Jun 16;57:342-66. doi: 10.1016/j.ejps.2013.08.024. Epub 2013 Aug 27. Review.

PMID:
23988843
13.

Oral bioavailability of cinnarizine in dogs: relation to SNEDDS droplet size, drug solubility and in vitro precipitation.

Larsen AT, Ohlsson AG, Polentarutti B, Barker RA, Phillips AR, Abu-Rmaileh R, Dickinson PA, Abrahamsson B, Ostergaard J, Müllertz A.

Eur J Pharm Sci. 2013 Jan 23;48(1-2):339-50. doi: 10.1016/j.ejps.2012.11.004. Epub 2012 Nov 21.

PMID:
23178440
14.

Binding processes determine the stereoselective intestinal and hepatic extraction of verapamil in vivo.

Thörn HA, Sjögren E, Dickinson PA, Lennernäs H.

Mol Pharm. 2012 Nov 5;9(11):3034-45. doi: 10.1021/mp3000875. Epub 2012 Oct 15.

PMID:
23009633
15.

Summary workshop report: Facilitating oral product development and reducing regulatory burden through novel approaches to assess bioavailability/bioequivalence.

Polli JE, Cook JA, Davit BM, Dickinson PA, Argenti D, Barbour N, García-Arieta A, Geoffroy JM, Hartauer K, Li S, Mitra A, Muller FX, Purohit V, Sanchez-Felix M, Skoug JW, Tang K.

AAPS J. 2012 Sep;14(3):627-38. doi: 10.1208/s12248-012-9376-z. Epub 2012 Jun 9.

16.

Extensive intestinal glucuronidation of raloxifene in vivo in pigs and impact for oral drug delivery.

Thörn HA, Yasin M, Dickinson PA, Lennernäs H.

Xenobiotica. 2012 Sep;42(9):917-28. doi: 10.3109/00498254.2012.683497. Epub 2012 May 4.

PMID:
22559211
17.

An investigation into the utility of a multi-compartmental, dynamic, system of the upper gastrointestinal tract to support formulation development and establish bioequivalence of poorly soluble drugs.

Dickinson PA, Abu Rmaileh R, Ashworth L, Barker RA, Burke WM, Patterson CM, Stainforth N, Yasin M.

AAPS J. 2012 Jun;14(2):196-205. doi: 10.1208/s12248-012-9333-x. Epub 2012 Feb 29.

18.

Drug metabolism of CYP3A4, CYP2C9 and CYP2D6 substrates in pigs and humans.

Thörn HA, Lundahl A, Schrickx JA, Dickinson PA, Lennernäs H.

Eur J Pharm Sci. 2011 Jun 14;43(3):89-98. doi: 10.1016/j.ejps.2011.03.008. Epub 2011 Apr 5.

PMID:
21447389
19.

Meeting report: applied biopharmaceutics and quality by design for dissolution/release specification setting: product quality for patient benefit.

Selen A, Cruañes MT, Müllertz A, Dickinson PA, Cook JA, Polli JE, Kesisoglou F, Crison J, Johnson KC, Muirhead GT, Schofield T, Tsong Y.

AAPS J. 2010 Sep;12(3):465-72. doi: 10.1208/s12248-010-9206-0. Epub 2010 Jun 2.

20.

Do gastrointestinal transit parameters influence the pharmacokinetics of gefitinib?

Wilson CG, O'Mahony B, Connolly SM, Cantarini MV, Farmer MR, Dickinson PA, Smith RP, Swaisland HC.

Int J Pharm. 2009 Jul 6;376(1-2):7-12. doi: 10.1016/j.ijpharm.2009.04.008. Epub 2009 Apr 14.

PMID:
19497691
21.

Clinical relevance of dissolution testing in quality by design.

Dickinson PA, Lee WW, Stott PW, Townsend AI, Smart JP, Ghahramani P, Hammett T, Billett L, Behn S, Gibb RC, Abrahamsson B.

AAPS J. 2008 Jun;10(2):380-90. doi: 10.1208/s12248-008-9034-7. Epub 2008 Aug 7. Review.

22.

The effects of pharmaceutical excipients on drug disposition.

Buggins TR, Dickinson PA, Taylor G.

Adv Drug Deliv Rev. 2007 Dec 22;59(15):1482-503. Review.

PMID:
18198495
23.

An investigation into the influence of drug lipophilicity on the in vivo absorption profiles from subcutaneous microspheres and in situ forming depots.

Deadman CM, Kellaway IW, Yasin M, Dickinson PA, Murdan S.

J Control Release. 2007 Sep 11;122(1):79-85. Epub 2007 Jun 22.

PMID:
17638603
24.
25.

An investigation of the disintegration of tablets in biorelevant media.

Anwar S, Fell JT, Dickinson PA.

Int J Pharm. 2005 Feb 16;290(1-2):121-7. Epub 2005 Jan 12.

PMID:
15664137
26.

Lung surfactant phospholipids inhibit the uptake of respirable microspheres by the alveolar macrophage NR8383.

Jones BG, Dickinson PA, Gumbleton M, Kellaway IW.

J Pharm Pharmacol. 2002 Aug;54(8):1065-72.

PMID:
12195820
27.

The inhibition of phagocytosis of respirable microspheres by alveolar and peritoneal macrophages.

Jones BG, Dickinson PA, Gumbleton M, Kellaway IW.

Int J Pharm. 2002 Apr 2;236(1-2):65-79.

PMID:
11891071
28.

Novel nanoparticles for pulmonary drug administration.

Dickinson PA, Howells SW, Kellaway IW.

J Drug Target. 2001;9(4):295-302.

PMID:
11697032
29.

An investigation of the solubility of various compounds in the hydrofluoroalkane propellants and possible model liquid propellants.

Dickinson PA, Seville PC, McHale H, Perkins NC, Taylor G.

J Aerosol Med. 2000 Fall;13(3):179-86.

PMID:
11066021
30.

Improved nasal bioavailability of FITC-dextran (Mw 4300) from mucoadhesive microspheres in rabbits.

El-Shafy MA, Kellaway IW, Taylor G, Dickinson PA.

J Drug Target. 2000;7(5):355-61.

PMID:
10721797
31.

Microcalorimetry does not predict the cellular phagocytosis of latex microspheres.

Jones BG, Gumbleton M, Kellaway IW, Dickinson PA.

Int J Pharm. 2000 Feb 15;195(1-2):17-23.

PMID:
10675677
32.

Prodrug to probe solution HFA pMDI formulation and pulmonary esterase activity.

Seville PC, Simons C, Taylor G, Dickinson PA.

Int J Pharm. 2000 Feb 15;195(1-2):13-6.

PMID:
10675676
33.

Transport of a series of D-phenylalanine-glycine hexapeptides across rat alveolar epithelia in vitro.

Evans JP, Tudball N, Dickinson PA, Farr SJ, Kellaway IW.

J Drug Target. 1998;6(4):251-9.

PMID:
9894693
34.

Putrescine uptake by alveolar epithelial cell monolayers exhibiting differing transepithelial electrical resistances.

Dickinson PA, Evans JP, Farr SJ, Kellaway IW, Appelqvist TP, Hann AC, Richards RJ.

J Pharm Sci. 1996 Oct;85(10):1112-6.

PMID:
8897281
35.

Pulmonary first-pass and steady-state metabolism of phenols.

Dickinson PA, Taylor G.

Pharm Res. 1996 May;13(5):744-8.

PMID:
8860431

Supplemental Content

Loading ...
Support Center